These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23868620)

  • 1. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study.
    Troisi G; Crisciotti F; Gianturco V; D'Ottavio E; Lo Iacono C; Formosa V; Bernardini S; Bellomo A; Marigliano B; Marigliano V
    Clin Ter; 2013; 164(3):203-7. PubMed ID: 23868620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
    Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.
    Kang H; Greenson JK; Omo JT; Chao C; Peterman D; Anderson L; Foess-Wood L; Sherbondy MA; Conjeevaram HS
    Am J Gastroenterol; 2006 Oct; 101(10):2247-53. PubMed ID: 17032189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [UDCA in the treatment of nonalcoholic fatty liver disease].
    Grigor'eva IN
    Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
    Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant correlations between severe fatty liver and risk factors for metabolic syndrome.
    Hsiao PJ; Kuo KK; Shin SJ; Yang YH; Lin WY; Yang JF; Chiu CC; Chuang WL; Tsai TR; Yu ML
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2118-23. PubMed ID: 18031368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid treatment of hepatic steatosis: a (13)C NMR metabolic study.
    Nunes PM; Jones JG; Rolo AP; Palmeira CM; Carvalho RA
    NMR Biomed; 2011 Nov; 24(9):1145-58. PubMed ID: 21538633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
    Kiyici M; Gulten M; Gurel S; Nak SG; Dolar E; Savci G; Adim SB; Yerci O; Memik F
    Can J Gastroenterol; 2003 Dec; 17(12):713-8. PubMed ID: 14679419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome.
    Mallea-Gil MS; Ballarino MC; Spiraquis A; Iriarte M; Kura M; Gimenez S; Oneto A; Guitelman M; Machado R; Miguel CM
    Acta Gastroenterol Latinoam; 2012 Mar; 42(1):20-6. PubMed ID: 22616493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF; Georgescu M
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
    Avalueva EB; Tkachenko EI; Skazyvaeva EV; Ivanov SV; Orishak EA; Lapinskiĭ IV
    Eksp Klin Gastroenterol; 2013; (11):26-30. PubMed ID: 24933975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
    Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
    J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [UDCA in the treatment of nonalcoholic fatty liver disease].
    Grigor'eva IN
    Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of NASH with ursodeoxycholic acid: pro.
    Ratziu V
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease--a common and benign finding in octogenarian patients.
    Kagansky N; Levy S; Keter D; Rimon E; Taiba Z; Fridman Z; Berger D; Knobler H; Malnick S
    Liver Int; 2004 Dec; 24(6):588-94. PubMed ID: 15566509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.